Xenon To Highlight Phase 3 X-TOLE2 & Long-Term Data For Azetukalner In Focal Onset Seizures At 2026 AAN Annual Meeting

(MENAFN - GlobeNewsWire - Nasdaq) Five abstracts accepted including Late-breaking Science oral and poster presentations of Phase 3 X-TOLE2 study results for azetukalner in focal onset seizures ...